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a b s t r a c t
Recent studies suggest a role for the arachidonic acid-derived epoxyeicosatrienoic acids (EETs) in
attenuating epileptic seizures. However, their effect on neurotransmission has never been investigated in
detail. Here, we studied how 11,12- and 14,15 EET affect excitability and excitatory neurotransmission in
mouse hippocampus. 11,12 EET (2 mM), but not 14,15 EET (2 mM), induced the opening of a hyper-
polarizing Kþ conductance in CA1 pyramidal cells. This action could be blocked by BaCl2, the G protein
blocker GDPb-S and the GIRK1/4 blocker tertiapin Q and the channel was thus identiﬁed as a GIRK
channel. The 11,12 EET-mediated opening of this channel signiﬁcantly reduced excitability of CA1 py-
ramidal cells, which could not be blocked by the functional antagonist EEZE (10 mM). Furthermore, both
11,12 EET and 14,15 EET reduced glutamate release on CA1 pyramidal cells with 14,15 EET being the less
potent regioisomer. In CA1 pyramidal cells, 11,12 EET reduced the amplitude of excitatory postsynaptic
currents (EPSCs) by 20% and the slope of ﬁeld excitatory postsynaptic potentials (fEPSPs) by 50%, pre-
sumably via a presynaptic mechanism. EEZE increased both EPSC amplitude and fEPSP slope by 40%, also
via a presynaptic mechanism, but failed to block 11,12 EET-mediated reduction of EPSCs and fEPSPs. This
strongly suggests the existence of distinct targets for 11,12 EET and EEZE in neurons. In summary, 11,12
EET substantially reduced excitation in CA1 pyramidal cells by inhibiting the release of glutamate and
opening a GIRK channel. These ﬁndings might explain the therapeutic potential of EETs in reducing
epileptiform activity.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Lipid signaling molecules in the central nervous system (CNS)
are diverse, including prominent eicosanoids such as the arach-
idonic acid (AA) derivatives endocannabinoids and prostaglandins.
Lesser known are the AA-derived epoxyeicosatrienoic acids (EETs),
which are synthesized by cytochrome P450 (CYP) epoxygenases.
Due to the four double bonds in AA, four EET regioisomers are
formed: 5,6-, 8,9-, 11,12- and 14,15-EET, with each regioisomer
consisting of a mixture of R/S and S/R enantiomers (Capdevila et al.,
2000). Although often considered as a single entity, several studies
suggest that EETs act in a regioisomer- and enantiomer-speciﬁc
manner (Ding et al., 2014; Lu et al., 2002; Node et al., 2001;
Wang et al., 2008; Zou et al., 1996).
Generally, the relative quantities of EET regioisomers vary with
the CYP isoenzyme present in the respective tissue. Of the 160 CYP
isoenzymes in the mouse, members of the CYP2C and CYP2J family
are most commonly considered to exert the highest epoxygenase
activity toward AA (Spector and Norris, 2007). However, it should
be noted that several other CYP isoforms also act as epoxygenases
and generate EETs such as rat CYP2D18 (Thompson et al., 2000) and
mouse CYP4X1 (Al-Anizy et al., 2006). The CNS cell types
expressing epoxygenases comprise endothelial cells, astrocytes and
neurons (reviewed in (Iliff et al., 2010b)). Speciﬁcally, the epox-
ygenases CYP4X1 (Al-Anizy et al., 2006), CYP2C29, CYP2C38 (Luo
et al., 1998), CYP2J9 (Qu et al., 2001), CYP2J8, CYP2J11, CYP2J13
(Graves et al., 2013) and CYP2J5 (Allen brain atlas (Lein et al., 2007),
http://www.brainmap.org) were identiﬁed inmouse brain. EETs are
released in a calcium- and activity-dependent manner from diverse
CNS cells, including sensory neurons (Sisignano et al., 2012) and
astrocytes (Alkayed et al., 1997). However, if they are exclusively* Corresponding author.
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synthesized on demand like most AA metabolites or released from
endogenous EET pools, in which they are present as esters of
glycerophopsholipids (Capdevila et al., 2000), is still disputed.
Earlier studies established EETs as potent vasodilators with a
central role in neurovascular coupling, the linking of neuronal ac-
tivity via astrocytes to evoke cerebral arteriolar dilatory responses
(Imig et al., 2011). Furthermore, EETs display angiogenic, anti-
apoptotic and anti-inﬂammatory properties, which together with
the vasodynamic effect probably underlie EET-mediated neuro-
protection (Koerner et al., 2007; Li et al., 2012; Liu et al., 2016b).
Further EET-mediated effects in the CNS include the release of
neuropeptides (Iliff et al., 2010a) and powerful anti-nociception,
which is observed after injection of 14,15 EET into the peri-
aqueductal gray, the primary control center for descending pain
modulation (Terashvili et al., 2008). The bioactivity of EETs is
limited by their hydrolysis to, reportedly, less active diols (dihy-
droxyeicosatrienoic acids, DHETs), a reaction catalyzed predomi-
nantly by soluble epoxide hydrolase (sEH) in the mouse brain
(Zhang et al., 2007). Consistent with this, inhibitors of sEH (sEHi)
effectively increase EET levels in vivo and have garnered wide-
spread attention for their potential therapeutic use in multiple
disorders such as hypertension, stroke, dyslipidemia, pain, immu-
nological and neurological diseases (Shen, 2010).
Still, the exact mechanisms by which EETs exert their various
effects remain poorly deﬁned. It is generally agreed that EETs may
function as autocrine and paracrine effectors. Potential molecular
targets include the KATP channel (Lu et al., 2002) and the calcium-
activated BK channel (BKCa) (Campbell et al., 1996; Li and
Campbell, 1997). More recently, EET-mediated modulation of TRP
channels has received attention with several studies reporting ef-
fects of EETs on TRPV4 (Earley et al., 2005; Vriens et al., 2005;
Watanabe et al., 2003), TRPC6 (Fleming et al., 2007), TRPA1
(Sisignano et al., 2012) and TRPV4-TRPC1 (Ma et al., 2015). How-
ever, EETs are less likely to bind to and activate an ion channel
directly. They are rather thought to activate a G protein-coupled
receptor (Carroll et al., 2006; Hayabuchi et al., 1998; Li and
Campbell, 1997), which activates a signal transduction pathway
that ultimately modulates ion channel functions.
Even thoughmost of the channels modulated by EETs arewidely
expressed in the CNS, little is known about the effects of EETs on
neuronal excitability and transmission. Three recent studies sug-
gest a possible involvement of EETs in the attenuation of
pharmacologically-induced epileptic seizures in mice: i) Seizures
generated by inhibition of the GABAergic system, but not by inhi-
bition of 4-AP sensitive Kþ channels, were attenuated by prior
application of a sEHi (Inceoglu et al., 2013); ii) Diazepam in com-
bination with a sEHi prevented progression of
tetramethylenedisulfotetramine-induced tonic seizures and
lethality in mice (Vito et al., 2014), and iii) sEHi treatment led to
signiﬁcant suppression of pilocarpine-induced seizures and an in-
crease in the seizure-induction threshold of fully kindled mice
compared to non-treated animals (Hung et al., 2015). However it
should be noted that EETs are not the only sEH substrates in the
brain; other substrates include epoxides from docosahexaenoic
acid (DHA) and eicosapentaenoic acid (EPA), which exert at least
partially similar effects to those observed with EETs (Morisseau
et al., 2010). While these reports implied that EETs suppress
rather than increase neuronal excitation, the only study examining
EET-mediated effects on neurotransmission did not afﬁrm this
notion. Indeed, 14,15-EET and the sEHi AUDA were both shown to
enhance excitatory synaptic transmission in mouse prefrontal
cortex, presumably by promoting the insertion of glutamatergic
receptors in the postsynaptic membrane (Wu et al., 2015).
In light of the recent evidence that EETs help to suppress
epileptic seizures, we hypothesized that EETs are strong
modulators of excitatory synaptic transmission and neuronal
excitability in the hippocampus, a brain region central for memory
and learning and often the starting point for temporal lobe epi-
lepsy. Speciﬁcally, we wanted a) to identify potential pre- and/or
postsynaptically located molecular targets, underlying the EET-
mediated effect and b) to test, if the so-called functional EET
antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (EEZE) (Gauthier
et al., 2002) is able to counteract EET-mediated actions on
neuronal transmission and excitability.
In this study, we recorded from CA1 pyramidal cells (PCs) in
mouse hippocampus, using the patch-clamp technique and ﬁeld
potential recordings, as well as the respective pharmacology to
isolate excitatory events. Finally, to address the question how
endogenous EETs affect epileptic seizures, the effect of the selective
sEHi tAUCB was studied on epileptiform activity in the
hippocampus.
2. Materials and methods
All experiments were performed in accordance with regulations
of the University of Zurich and the veterinary department of the
canton of Zurich, Switzerland, for animal handling and
experimentation.
2.1. Immunohistochemistry
Distribution of CYP2J protein was visualized by immunoperox-
idase staining of parasagittal sections from perfusion-ﬁxed tissue of
male 10 week-old C57Bl/6 mice. Mice were deeply anesthetized
with Nembutal and perfused with 4% paraformaldehyde in 0.15 M
phosphate buffer (pH 7.4). Brains were post-ﬁxed for 3 h, cry-
oprotected with sucrose and sectioned with a microtome (40 mm).
Sections were incubated overnight at 4 C with the CYP2J antibody
(rabbit, diliuted 1:1000 (Qu et al., 2001) in Tris buffer, pH 7.4 con-
taining 2% normal goat serum and 0.2% Triton-100. The next day, a
biotinylated secondary antibody directed against rabbit (1:300
Jackson ImmunoResearch, West Grove, PA, USA) was applied for
30 min, followed by Vectastain elite kit processing (Vector Labo-
ratories, Burlingame, CA, USA) and incubation with dia-
minobenzidine as chromogen. Sections were mounted onto
gelatin-coated glass slides, air-dried, dehydrated, and cover-
slipped with Eukitt. Images were digitized with a high-resolution
camera and processed using the software Mosaic (ExploraNova,
La Rochelle, France).
2.2. Hippocampal slice preparation
C57Bl/6J mice were obtained from Charles River laboratories
(Freiburg, Germany). Transverse hippocampal slices (350e400 mm
thick) of male, 3e4 week old mice were obtained using a vibrating
blade microtome, HM 650 V (Thermo Scientiﬁc, UK). Brieﬂy, a
mouse was anaesthetized and euthanized by decapitation. The
brain was extracted and immediately transferred into ice-cold
artiﬁcial cerebrospinal ﬂuid (ACSF) equilibrated with 95% O2 and
5% CO2 containing (in mM) NaCl (125), CaCl2 (2.5), MgCl2 (1),
NaHCO3 (26), KCl (2.5), NaH2PO4 (1.25) and glucose (10). Slices were
immediately transferred to an incubating chamber with ACSF at
35 C for 20 min and thereafter kept at room temperature.
2.3. Electrophysiology
Slices were mounted on poly-L-lysine-coated coverslips and
transferred to the recording chamber, where they were continu-
ously superfused with ACSF at a rate of 1.8 ml/min. All experiments
were performed at 30e32 C using an in-line heating system.
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Hippocampal formation and CA1 PCs were visualized by using an
upright microscope (BX51Wl, Olympus), equipped with a 20x
water-immersion objective, infrared/differential interference
contrast (DIC) optics and an infrared video imaging camera (VX55,
Till Photonics).
Patch pipettes with tip resistances of 3e5 MU were pulled from
borosilicate glass (GC150F-10, Harvard apparatus, UK) with a hor-
izontal puller (Zeitz instrument, Germany). For most experiments,
pipettes were ﬁlled with a K-gluconate based internal solution
containing (in mM): K-gluconate (145), EGTA (1), HEPES (10),
MgATP (5), NaGTP (0.5) and NaCl (5). The pH was adjusted to 7.3
with KOH; osmolarity was 295e305 mOsm. For one set of experi-
ments a CsCl-based internal solution was used containing (in mM):
CsCl (100), MgCl2 (2), EGTA (0.1), MgATP (2), NaGTP (0.3) and HEPES
(40). The pH was adjusted to 7.3 with CsOH; osmolarity was
290e300 mOsm. For the recordings of evoked excitatory post-
synaptic currents (EPSCs), CA1 PCs were held at a holding potential
of Vh ¼ 70 mV and a glass capillary ﬁlled with ACSF was placed in
stratum radiatum on Schaffer collaterals (SCs). Stimuli were given
at 0.1 Hz. Bicuculline (25 mM) was present throughout the entire
experiment to block inhibitory transmission. To assess the paired
pulse ratio, paired stimuli with interstimulus intervals of 50 ms
were given. For miniature EPSCs (mEPSCs) recordings, tetrodotoxin
(TTX, 1 mM) and bicuculline (25 mM) were added to the bath solu-
tion. Ramp recordings were carried out in presence of TTX (1 mM)
with CA1 PCs initially voltage clamped at Vh ¼ 70 mV and then
ramped from 120 mV to 50 mV in 0.6 s. Before the start of a
ramp experiment, cells were held in current clamp mode and
current pulses of 10 pA were injected to determine the resting
membrane potential (RMP), capacitance, and the input resistance
Rinput of the cell. EET-induced currents were normalized to cell
capacitance and expressed as pA/pF. To monitor series resistance RS
and Rinput throughout voltage-clamp recordings, a hyperpolarizing
pulse of5mV (50 ms) was given at constant intervals. Recordings,
in which RS changed more than 20% were discarded. To assess the
spiking ability of CA1 PCs, cells were held in current clamp and a
rectangular current (0.8 s) was injected every minute with the
amplitude adapted to the individual cell such that a robust number
of action potentials was evoked. EET- and EEZE-induced changes in
RMP and the numbers of action potentials were analyzed. Field
excitatory postsynaptic recordings (fEPSPs) were recorded in
400 mm thick hippocampal slices with an ACSF-ﬁlled glass pipette
used as recording pipette. fEPSPs were evoked by stimulating SCs at
0.1 Hz, using a wide-tip ACSF-ﬁlled glass capillary. Stimulation in-
tensity, ranging from 20 to 150 mA, was adapted for each recording
to obtain a sub-maximal fEPSP signal with minimal non-synaptic
contamination. For the recording of population spikes and
bicuculline-induced epileptic discharges, the stimulating electrode
was again placed on SCs, the recording electrode on stratum
pyramidale.
Data were recorded with a Multiclamp 700B ampliﬁer (Axon
instruments), ﬁltered at 3e10 kHz and digitized at 20 kHz (A/D
hardware from National instruments). Data were acquired and
analyzed with IGOR Pro software (Wave Metrics, Lake Oswego).
Spontaneous events were analyzed off-line with the Mini Analysis
Program (Synaptosoft). Prism 5 (GraphPad, USA) was used for
statistical analysis and preparation of the graphs. Appropriate sta-
tistical tests were employed as indicated. Results of several exper-
iments are presented as average values ± standard error of mean
(SEM).
2.4. Pharmacology
All drugs were bath applied except GDPbS, which was dissolved
in the internal solution. Stock solutions of tAUCB (trans-4-(4-[3-
adamantan-1-yl-ureido]-cyclohexyloxy)-benzoic acid; 10 mM;
kindly provided by C. Morisseau) and bicuculline (Tocris) were
prepared in DMSO. Stocks for Guanosine-50-O (2-
thiodiphosphate)(GDPßS)sodium salt (10 mM; Biolog, Germany),
BaCl2 (1 M; Sigma-Aldrich, Germany) and tetrodotoxin citrate
(1 mM; ANAWA, Switzerland) were prepared in puriﬁed water
(Millipore Systems, USA). EEZE, (±)11,12- and (±)14,15-EETs as well
as 11,12-DHET were obtained from Cayman (Adipogen,
Switzerland), dissolved in ethanol. They were dried under nitrogen
gas and re-dissolved in ACSF (1e10 mM) before bath-application.
3. Results
3.1. CYP2J epoxygenase expression in mouse hippocampus
Detailed expression pattern for CYP epoxygenases in mouse
hippocampus are rare. To our knowledge the only cellular distri-
bution pattern so far available is the one for the isoenzyme CYP2J5,
which is however based on mRNA expression (Allen brain atlas
(Lein et al., 2007)). We studied the expression pattern of CYP2J
proteins (as an example for a family of epoxygenases) by immu-
nohistochemistry in brain slices from C57Bl/6J mice, using a CYP2J
pan antibody (Qu et al., 2001). In the hippocampus, strong CYP2J
immunoreactivity (IR) was detected in cell bodies of CA1-CA3 PCs
as well as in their apical and basal dendritic ﬁelds with particularly
strong IR detected in apical dendrites of CA1 PC in the stratum
radiatum (See Fig. 1a).
3.2. Effects of tAUCB, 11,12-EET and EEZE on CA1 synaptic
transmission
To ensure that exogenously applied EETs were not immediately
eliminated by sEH, the dominant epoxide hydrolase in mouse
hippocampus (Marowsky et al., 2009), the potent and selective sEHi
tAUCB (Hwang et al., 2007) was used. In a ﬁrst experiment, we
tested if tAUCB alone exerted any effects on synaptic transmission.
Stimulating SCs, we recorded EPSCs in CA1 PCs; tAUCB (1 mM) was
bath-applied. EPSC amplitude, kinetic parameters (rise time and
decay constants) as well as the holding current Ihold were not
affected by tAUCB (Fig. 1b, Suppl.Table 1). All subsequent experi-
ments in which EETs were applied were therefore carried out in
presence of 1 mM tAUCB.
Of the four EET regioisomers, we chose the ones synthesized in
highest quantities in the hippocampus, 11,12 and 14,15 EET
(Sanchez-Mejia et al., 2008). The focus was on the 11,12-
regioisomer, additional experiments were conducted with 14,15
EET for comparison. First, we evaluated the effect of 11,12 EET on
EPSCs in CA1 PCs, voltage-clamped at Vh ¼ 70 mV. EPSCs were
evoked by two consecutive stimuli with an interstimulus interval of
50 ms in presence of bicuculline (25 mM) to block inhibitory
transmission. Bath-application of 11,12 EET (2 mM) led to a rapid
and signiﬁcant reduction of both EPSC amplitudes with the ﬁrst
amplitude reduced to 78 ± 5% (n ¼ 5, paired Student's t test,
p ¼ 0.0256*) and the second to 86 ± 4% (p ¼ 0.0481*, Fig. 1c, c1, e).
Comparison of the paired pulse ratio (PPR: Amp2/Amp1) under
control conditions and in presence of EETs revealed an increase
from 1.94 ± 0.13 to 2.15 ± 0.1 (paired Student's t test, p ¼ 0.032*).
Such a change in paired-pulse facilitation is usually an indication
for a presynaptic site of action. We next tested if the antagonist
EEZE is able to block the EET-induced reduction of EPSCs. Appli-
cation of EEZE (10 mM) signiﬁcantly potentiated both EPSC ampli-
tudes (Fig. 1d, d1) to 141 ± 10% (Amp1, n¼ 9, paired Student's t test,
p ¼ 0.0026**) and 119 ± 8, respectively (Amp2, p ¼ 0.043*). The
concomitant change in the PPR from 2.13 ± 0.11 to 1.77 ± 0.10
(Fig. 1f; p ¼ 0.00078***) again pointed to a presynaptic site of
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action. Surprisingly, prior application of EEZE followed by 11,12 EET
was unable to prevent EET-mediated reduction of EPSC amplitudes
(Fig. 1d). Moreover, even in the presence of EEZE, EETs still seemed
to exert their effect by a presynaptic mechanism as indicated by the
change in the PPR (Fig. 1f). (Detailed data for evoked EPSC re-
cordings are shown in Suppl. Table 2).
To examine in more detail the presynaptic actions of EETs and
EEZE, we next recorded mEPSCs in CA1 PCs in presence of TTX
(1 mM) to abolish action potentials. mEPSCs are due to random
release of single presynaptic glutamate vesicles at different syn-
aptic sites. While application of 11,12 EET affected neither mEPSC
amplitude nor frequency (n ¼ 5, Fig. 2a-a2, c), EEZE led to a rapid
increase in the occurrence of mEPSCs, shown in Fig. 2b, b1 and
d (n ¼ 5). However, EEZE had no consistent effect on mEPSC am-
plitudes in CA1 PCs (Fig. 2b2, d). (Detailed data for mEPSCs re-
cordings are shown in Suppl. Table 3). A change inmEPSC frequency
is usually attributed to effects on quantal transmitter release and as
such the effect is undisputedly of presynaptic origin. Taken
together, the results indicate that EEZE affects transmitter release in
the absence of action potentials, whereas 11,12 EET has no effect
under these conditions. This strongly suggests two different pre-
synaptic molecular targets.
In addition to the effect on EPSC amplitude, we observed
another striking effect in some of the evoked EPSC and mEPSC
experiments: The holding current Ihold was substantially modu-
lated by 11,12 EET (see Figs. 2a and 3a), in a manner compatible
with an increase in outward current. Re-analysis of the EET-
mediated effect on Ihold in mEPSC recordings revealed that on
average Ihold increased robustly by þ21 ± 4 pA (n ¼ 6, Student's
paired t test p ¼ 0.00615**, Fig. 3c, Suppl. Table 3). This increase in
Ihold was accompanied by a decrease in input resistance (Fig. 3d),
indicative of channel opening and the activation of a conductance.
To gain further insight into the nature of the conductance, we
repeated these experiments with a CsCl-based internal solution, as
Csþ is known to block Kþ -conducting ion channels. Under these
conditions, relative to the control, DIhold and Rinput were unchanged
upon application of EETs (Fig. 3c,e). This demonstrates that no
further conductance was activated and suggests that 11,12 EET ac-
tivates a postsynaptic Kþ current.
3.3. Characterization of the 11,12 EET-induced current
For a more detailed characterization of the EET-activated cur-
rent, we investigated its current-voltage relationship. To this end,
current-voltage curveswere obtained (n¼ 5) in the presence of TTX
(1 mM). The 11,12 EET-induced current reversed at 102 ± 6 mV
(Fig. 4a). These experiments were carried out with an extracellular
Kþ concentration of 2.5 mM and an internal Kþ concentration of
145 mM (using a K-gluconate internal solution), therefore accord-
ing to the Nernst equation the calculated Kþ reversal potential
was106mV at 32 C. The reversal potential determined by us was
compatible with a Kþ current. For comparison, the same experi-
ment was conducted with 14,15 EET (2 mM, n ¼ 4); however, 14,15
EET failed to open any conductance in CA1 PCs (Fig. 4b). To narrow
down the spectrum of possible Kþ channel candidates, we bath-
applied 500 mM BaCl2, a classical inhibitor of G protein-coupled
Fig. 1. 11,12 EET reduces, but EEZE potentiates EPSCs recorded in CA1 PCs.
a) CYP2J expression in mouse hippocampal formation illustrated by immunoperoxidase staining. Note the strong CYP2J IR in pyramidal cell bodies and particularly in CA1 dendrites,
while dentate gyrus granule cells are spared. Scale bar: 250 mm; b) Representative traces of EPSCs before (upper graph) and after tAUCB (lower graph); summary of EPSC parameters
are presented in Suppl. Table 1; c) Plot of EPSC peak amp 1 vs. time for a representative CA1 PC with the horizontal line indicating the time of bath-application of 2 mM 11,12 EET; c1)
Average of 10e20 traces from c) before and after application of 11,12 EET; d) Plot of EPSC peak amplitude vs. time for a representative CA1 PC exposed to the functional EET-
antagonist EEZE (10 mM), followed by 11,12 EET (2 mM) as indicated by the horizontal lines; d1) Average of 10e20 traces before and after application of EEZE and 11,12 EET; e)
Summary of the effect of 11,12 EET (2 mM), EEZE (10 mM) and 11,12 EET (2 mM) þEEZE(10 mM) on EPSC amp; 1-way-ANOVA followed by Bonferroni, post-hoc analysis; for detailed
data and statistics see Suppl. Table 2; f) Application of 11,12 EET, EEZE or 11,12 EET in presence of EEZE signiﬁcantly changes the PPRs, suggesting presynaptic molecular targets for
these compounds. p < 0.05*, p < 0.01**, p < 0.001***. Abbreviations: CA cornu ammonis; DG dentate gyrus; DGGC dentate gyrus granule cells; SR stratum radiatum.
N.K. Mule et al. / Neuropharmacology 123 (2017) 310e321 313
Fig. 2. EEZE modulates mEPSC frequency.
a) Representative trace of a mEPSC recording in a CA1 PC with application of 11,12 EET (2 mM) indicated by the horizontal line. Short horizontal lines marked with A) and B) denote
stretches that are shown enlarged below to resolve the individual events, marked by asterisks; a1) Frequency histogram for the mEPSC trace to the left; a2) Cumulative probability
plot depicting mEPSC amplitudes before and after addition of 11,12 EET for the mEPSC recording to the left. b) Representative trace of a mEPSC recording in a CA1 PC with
application of EEZE (10 mM) indicated by the horizontal line. Horizontal lines marked with C) and D) denote short stretches shown enlarged below; b1) Frequency histogram for the
mEPSC trace to the left; b2) Cumulative probability plot depicting mEPSC amplitudes before and after addition of EEZE for the mEPSC recording to the left; c) Summary of the 11,12
EET effect on mEPSC frequency and amplitude in CA1 PCs; d) Summary of the EEZE effect on mEPSC frequency and amplitude in CA1 PCs.
co
ntr
ol
11
,12
 E
ET
0
100
200
300
R i
np
ut
 (
M
)
KG
luc
Cs
Cl
-20
0
20
40
I h
ol
d
(p
A
)
)c)a
b)
KGluc
CsCl
*** *
co
ntr
ol
11
,12
 E
ET
0
100
200
300
R i
np
ut
 (
M
)
20 pA
1 min
Ihold
d) e)KGluc CsCl11,12 EET
11,12 EET
Fig. 3. 11,12 EET opens a postsynaptic Cs-sensitive conductance.
a) and b) representative traces of mEPSCs, Vh ¼ 70 mV, recorded with a K-gluconate -based (a) and a CsCl-based (b) internal solution with 11,12 EET (2 mM) application indicated by
horizontal lines. 11,12 EET potentiates the outward current only with the K-gluconate-based internal solution; c) and d) Summary of 11,12 EET-mediated changes in Ihold and Rinput,
recorded in CA1 PCs with the two different internal solution. p < 0.05*, p < 0.001***.
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inward rectiﬁer potassium (GIRK) channels (Sodickson and Bean,
1996), prior to 11,12 EET application (n ¼ 8; Fig. 4a). In the pres-
ence of BaCl2, 11,12 EET was unable to open a conductance. Since
activation of GIRK channels modiﬁes substantially the RMP of a
neuron to more negative values, we next recorded CA1 PCs in
current-clamp mode and monitored RMP before and after appli-
cation of 11,12 EET; kynurenic acid and bicuculline were present
throughout the experiment to suppress any spontaneous synaptic
transmission. 11,12 EET hyperpolarized CA1 PC from67.8 ± 1.8 mV
to 70.9 ± 1.6 mV (Fig. 4d; n ¼ 9, paired Student's t test
p ¼ 0.000217***) with an average of DRMP of 3.1 ± 0.5 mV
(Fig. 4h).
EETs may open a GIRK channel either directly or via a G protein.
To distinguish between these two scenarios, the G protein blocker
GDPbS (1 mM) was included in the internal solution; to ensure
complete diffusion, cells were dialyzed 20 min before the start of
the recording (n ¼ 5). GDPbS completely abolished EET-mediated
hyperpolarization (Fig. 4c,e), verifying the involvement of a G-
protein and refuting the notion of direct activation of a GIRK
conductance by EETs. Final evidence for the EET-mediated activa-
tion of a GIRK current was obtained by bath-application of the
selective GIRK1/4 (Kir3.1/3.4) blocker tertiapin Q (TTQ, 1 mM) prior
to application of EETs. Under these conditions, 11,12 EET was unable
to open an additional hyperpolarizing membrane conductance, and
cells tended to depolarize slightly instead (n ¼ 5, Fig. 4h).
EEZE alone had no effect on RMP and was unable to block EET-
induced hyperpolarization in CA1 PCs, when washed in prior to
11,12 EET (Fig. 4f, h). Furthermore, the diol, 11,12 DHET (5 mM) was
unable to induce a signiﬁcant change in the RMP of CA1 PCs (Fig. 4g
and h). Taken together, these results show that 11,12 EET opens, via
a G protein-coupled mechanism, a GIRK 1/4 conductance in CA1
PCs, which leads to the observed hyperpolarization in these cells.
To assess if, and to what degree, the EET-activated GIRK current
affects excitability of CA1 PCs, we studied the spiking ability of
these cells in presence of 11,12 EET and EEZE. CA1 PCs were held in
current-clamp mode and injected with a current pulse (Fig. 5a) to
elicit a short train of action potentials. The injected current was
adapted to the individual cell, ranging from þ70 to þ150 pA. Bath-
application of 11,12 EET led to a hyperpolarization similar to that
seen before (3.4 ± 0.5, n ¼ 9, data not shown) and reduced
signiﬁcantly the number of spikes to 76±%3 (n¼ 9, paired Student's
t test p ¼ 0.00012***; Fig. 5b). In presence of EEZE, the number of
spikes was unchanged (n ¼ 7, paired Student's t test, p ¼ 0.175,
Fig. 5c and d), and subsequent application of 11,12 EET reduced the
number of spikes in a similar manner to that observed with 11,12
EET alone (75.0 ± 6%, paired Student's t test, p ¼ 0.00018***; Fig. 5c
and d).
3.4. Net effects of EETs and EEZE on hippocampal fEPSPs
Next, we addressed if as a net effect in the hippocampus EETs
and EEZE dampen or increase excitatory neurotransmission. To this
Fig. 4. 11,12 EET activates a GIRK1/4 conductance in CA1 PCs.
a)Voltage-clamp recordings of CA1 PCs with a K-gluconate-based internal solution. Red trace: A voltage ramp from 120 to 50 mV was applied in control condition and after bath
application of 11,12 EET (2 mM). Control traces were subtracted from EET traces; the red trace represents the average of n ¼ 5 cells. Blue trace: The same voltage ramp was applied in
presence of 500 mM BaCl2 followed by 11,12 EET (2 mM). BaCl2 traces were subtracted from BaCl2 þ 11,12 EET traces. The blue trace represents the average of n ¼ 8 cells. b) The same
as a) with 14,15 EET (2 mM). The trace represents the average of n ¼ 4 cells. Due to the lack of effect of 14,15 EET, no experiments were carried out in presence of BaCl2; c) Example of
current-clamp recordings of CA1 PCs to monitor RMP. The control cell (white circles) was dialyzed with normal K-gluconate based internal solution, while the other (gray circles)
was dialyzed with the same internal solution containing 1 mM GDPbS. 11,12 EET (2 mM) was applied as indicated by the horizontal line; d) Average effect of 11,12 EET (2 mM) on RMP
of control cells with normal internal solution; e) Comparison of 11,12 EETs-induced RMP change between control cells and those dialyzed with 1 mM GDPbS; f) Application of EEZE
(10 mM) prior to 11,12 EET (2 mM) did not prevent EET-induced hyperpolarization in CA1 PCs, example trace of a representative cell; g) Application of 11,12 DHET had no effect on
RMP, example trace of a representative cell; h) Summary graph of RMP changes after application of 11,12 EET (2 mM) or EEZE (10 mM) or 11,12 DHET (5 mM) alone, and in slices
pretreated with EEZE (10 mM) or the selective GIRK1/4 blocker tertiapin Q (TTQ, 1 mM) followed by 11,12 EET (2 mM). (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
N.K. Mule et al. / Neuropharmacology 123 (2017) 310e321 315
end stimulating and recording electrodes were both placed in
stratum radiatum on SCs (see scheme, Fig. 6a) and fEPSPs, evoked
by two consecutive stimuli with an interstimulus interval of 50 ms,
were recorded with inhibitory transmission left intact. Although
under these conditions inhibition is not recorded directly, it is
known to substantially modulate and shape hippocampal fEPSPs
(Chapman et al., 1998). Unexpectedly, application of tAUCB (1 mM)
resulted in a small, but signiﬁcant decrease of fEPSP slopes and
amplitudes, presumably due to effects exerted by accumulation of
endogenous EETs (Fig. 6e, Table 1). Subsequent application of 11,12
Fig. 5. 11,12 EET decreases excitability in CA1 PCs.
a) Representative current-clamp recording of a CA1 PC with response to somatic current injection (80 pA) before (left) and after the application of 11,12 EET (2 mM, right); b) Graph
showing how the number of spikes in individual CA1 PCs (black circles) changes in presence of 11,12 EET (2 mM). The average of all cells is shown in gray circles; c) Representative
current-clamp recording of a CA1 PC with response to somatic current injection (130 pA) before (left) and after the application of EEZE (10 mM, middle), followed by application of
11,12 EET (2 mM, right); d) Graph showing how the number of spikes in individual PCs (black circles) changes in presence of EEZE (10 mM) followed by 11,12 EET (2 mM). Average of all
cells is shown in gray circles. p < 0.001***.
Fig. 6. 11,12 EET and 14,15 EET decrease, EEZE potentiates hippocampal fEPSPs.
a) Schematic drawing of a hippocampal slice, showing the localization of recording and stimulation electrode; b) Representative fEPSP slope vs. time graph with the application of
11,12 EET (2 mM) indicated by the gray horizontal line; b1) Average of 20e30 traces before and after application of 11,12 EET; c) and c1) Same as b) and b1) for 14,15 EET (2 mM); d) and
d1) Same as b) and b1) for EEZE (10 mM); e) Summary graph showing the effects of the different compounds on fEPSP slope 1; 1-way ANOVA followed by Bonferroni post hoc
analysis: all comparisons p < 0.001*** except for tAUCB vs 14,15 EET. For further statistics employing paired Student's t test see Table 1; f) Both EET regioisomers and EEZE change
the respective PPRs signiﬁcantly, pointing towards a presynaptic mechanism. DG dentate gyrus; SC Schaffer collaterals. p < 0.01**.
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EET led to a signiﬁcant reduction of fEPSP slope1 to 52.4 ± 4.5% and
slope2 to 60.2 ± 4.0%, respectively (Fig. 6b,b1,e; for detailed data
and fEPSP statistics, see Table 1). In comparison to 11,12 EET, 14,15
EET was less potent, only reducing fEPSP slope1 to 80.8 ± 4.6% of
baseline values (see Fig. 6c, c1, e). Both 11,12 EET and 14,15 EET
signiﬁcantly increased the PPR (Fig. 6f), further supporting the
existence of a presynaptic target. By contrast, EEZE markedly
potentiated fEPSP slope 1 and amplitude 1 to 140% and 136%,
respectively (Fig. 6d, d1, e). Since the potentiating effect was less
pronounced for the second slope and amplitude, the PPR decreased
under EEZE (Fig. 6f), again consistent with previous observations
pointing towards a presynaptic site of action. Taken together, 11,12
and 14,15 EETs both reduce excitatory neurotransmission in the
hippocampus with 11,12 EET being the more potent of the two. By
contrast, EEZE increases excitatory transmission in the hippocam-
pus, and is not capable of antagonizing the EET-mediated reduction.
3.5. tAUCB effect on epileptic discharges in the hippocampal
formation
The tAUCB-mediated reduction of fEPSPs suggested that re-
cordings from a population of neurons (rather than from a single
neuron) might allow for the detection of effects exerted by
endogenous EETs, released and accumulated in the brain slice. In a
ﬁnal experiment we therefore addressed the effect of tAUCB on
epileptiform activity in brain slices. It is known that reduced
GABAergic inhibition easily leads to large-scale synchronization
and epileptic discharges in the hippocampal network. Thus, we
applied bicuculline and, to get a better estimate of the synchronous
action potential ﬁring, recorded population spikes by placing the
recording electrode on the stratum pyramidale. As expected,
bicuculline (25 mM) led to a dramatic change in the waveform of
single-pulse evoked population spikes (see Fig. 7a) and also sub-
stantially increased their amplitude and duration. To quantify the
intensity of these epileptic-like bursts, we chose the so-called
coastline bursting index CBI (Korn et al., 1987; Riekki et al., 2008).
Essentially, beginning and end of the burst waveformwere marked
and the total duration was measured (see arrows in Fig. 7a). After
10 min, application of bicuculline resulted in a marked increase in
CBI from 25.6 ± 1.5 to 62.0 ± 3.7 ms (p ¼ 0.00062***, n ¼ 5, paired
Student's t test). By contrast, tAUCB (1 mM) reduced the CBI slightly,
but signiﬁcantly (Fig. 7b, d; p ¼ 0.0077**, n ¼ 6). When bicuculline
was subsequently applied, it led to much less dramatic bursting
(Fig. 7b,d) compared to bicuculline alone (Fig. 7e, unpaired Stu-
dent's t test p ¼ 0.000136***). This showed that tAUCB, most likely
via stabilizing endogenous EETs, is capable of reducing epileptiform
discharges in brain slices consistent with recent data obtained in
systemic epilepsy models in rodents.
Table 1
Summary of effects on fEPSPs.
Substance Slope 1 Slope 2 Amp1 Amp2 n Compared to
tAUCB (1 mM) 89.2 ± 3.2* 90.8 ± 3.0* 91.4 ± 3.2* 92.2 ± 3.1* 8 untreated
11,12 EET (2 mM) 52.4 ± 4.5*** 60.2 ± 4.0*** 52.8 ± 4.6*** 59.4 ± 5.2** 7 tAUCB
14,15 EET (2 mM) 80.8 ± 4.6* 85.5 ± 4.2* 84.5 ± 5.0* 86.1 ± 4.3* 7 tAUCB
EEZE (10 mM) 142.2 ± 4.6*** 123.3 ± 3.0** 136.1 ± 9.1** 125.5 ± 5.3** 7 untreated
Values are given as mean percentage ±SEM. For each compound normalized comparisons were carried out as indicated in the furthest column to the right. Asterisks indicate
the signiﬁcant difference obtained from these comparisons. (p < 0.05*, p < 0.01**, p < 0.001***, paired Student's t test). n number of experiments performed.
Fig. 7. tAUCB attenuates burst-like activity in the hippocampal formation.
a) Representative graphs of single-pulse evoked population spikes recorded from stratum pyramidale under control conditions (untreated slice; left) and 10 min after washing in of
bicuculline (25 mM; right). Arrows indicate the total duration, used to calculate the respective CBI; b) Representative graphs of single-pulse evoked population spikes recorded under
control conditions (untreated slice; left), after application of tAUCB (1 mM; middle), which was followed by application of bicuculline (25 mM; right). tAUCB and bicuculline graphs
were taken each 10 min after start of bath-application of the respective compound; c) Summary graph for a), showing how CBI in individual experiments changes after application
of bicuculline; d) Summary graph for b), showing how CBI changes under tAUCB and subsequently under bicuculline; e) Comparison of the normalized CBI observed under
bicuculline on untreated slices and the CBI observed in slices pretreated with tAUCB. p < 0.01**; p < 0.001***.
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4. Discussion
The present study has four major ﬁndings: First, 11,12 EET and to
a lesser degree 14,15 EET inhibit EPSCs and fEPSPs in the hippo-
campus, thus reducing excitatory transmission. Second, 11,12 EET
exerts its effect by acting on both pre- and postsynaptic targets in
CA1 PCs, whereas the 14,15 EET-mediated effect seems limited to a
presynaptic target. Third, postsynaptically, 11,12 EET opens a Kþ
conductance via activation of a G protein, resulting in hyperpolar-
ization and attenuated excitability of CA1 PCs. Finally, the func-
tional antagonist EEZE seems to exclusively act via a presynaptic
target, which with high probability differs from the one activated
by 11,12 EET.
4.1. 11,12 EET-mediated hyperpolarization involves the opening of
GIRK1/4 channels most likely via activation of Gai/o proteins
We observed a 11,12 EET-speciﬁc opening of a hyperpolarizing
current, which we identiﬁed as a Kþ current due to its reversal
potential and the fact that it could be blocked by intracellular Csþ.
Since dialyzing the cell with the G protein blocker GDPbS prevented
the EET-mediated opening of the Kþ current, a direct effect of EETs
appeared unlikely and suggested that the activation of a G protein is
a prerequisite. Both BaCl2 and tertiapin Q blocked the 11,12 EET-
mediated opening of the Kþ conductance and these ﬁndings
together with the IV-curve (Fig. 4a) provide compelling evidence
that 11,12 EET opens a GIRK channel in CA1 PCs. GIRKs usually
require activation by the b/g subunit of Gi/o proteins, whereas Gs
proteins only activate GIRK under nonphysiological conditions (e.g.
following overexpression) (Dascal and Kahanovitch, 2015). How-
ever, studies focusing on intracellular pathways activated by EETs
exclusively reported the involvement of Gs proteins. It needs to be
noted, however, that all these studies used non-neuronal cells, e.g.
endothelial cells (Ding et al., 2014; Node et al., 2001), preglomerular
microvessels (Carroll et al., 2006), coronary arteries (Li and
Campbell, 1997) and HEK cells (Fukao et al., 2001), implying that
the cell type is of central importance as to which G protein is
activated by EETs. Taken together, our discovery of the 11,12 EET-
mediated opening of a GIRK channel, including the activation of
Gi/o proteins, constitutes a so far undescribed, new cellular
pathway. This result may also shed new light on previous ﬁndings
that EETs contribute to m-opioid receptor-mediated anti-noci-
ception (Conroy et al., 2010; Terashvili et al., 2008), a GPCR system
commonly linked to Gi/o proteins.
4.2. Potential postsynaptic targets for 11,12 EET in CA1 PCs
A large body of data, accumulated over the last three decades,
suggests that EETs act through a speciﬁc binding site, most likely a
cell surface receptor (Chen et al., 2009; Falck et al., 2003; Snyder
et al., 2002). Because the majority of EET-mediated physiological
responses occur with nanomolar concentrations, the existence of a
high-afﬁnity EET-receptor was proposed. We used low micro-
molecular concentrations (2 mM) of 11,12 EET throughout our study,
but it is difﬁcult to relate that to the ﬁnal concentration reaching to
the recording spot in brain slice. Tissue preparations are notorious
for their ability to take up and sequester lipophilic, detergent-like
compounds like EETs, which was also evident in our recordings
as EET-mediated effects were difﬁcult to reverse via wash out (see
Fig. 6b with the effect lingering for 20 min after EET application).
Furthermore, in our hands 11,12 EET concentrations in the nano-
molar range produced extremely inconsistent results, often failing
to elicit any response, which we attributed to the highly lipophilic
nature of the compound. As a result, it was not possible to establish
a meaningful dose-response relation and we decided to use a ﬁxed
concentration that gave reproducible results.
Although an EET-speciﬁc GPCR still awaits identiﬁcation, some
well-characterized GPCRs have been identiﬁed to which EETs, and
speciﬁcally 11,12 EET, reportedly bind; these include the cannabi-
noid receptors CB1 and CB2, the dopamine receptor D3 and the
GPR40. However, it takes 11,12 EET concentrations in the 100
micromolar range to displace high-afﬁnity radio ligands from CB1,
CB2 and D3 receptors (Inceoglu et al., 2007). EC50 values for the
human GPR 40 are in a comparatively lower range with 6e8 mM
(Itoh et al., 2003). Still, the GPR 40 constitutes an unlikely candidate
for two reasons: 1.) EETs and DHETs were shown to activate the
GPR40 to a similar degree (Itoh et al., 2003), while in our study only
11,12 EET, but not the corresponding DHET, was capable to activate a
GIRK channel (see Fig. 4g). Furthermore, the GPR 40 is reportedly
coupled to Gq/11 (Briscoe et al., 2003) and thus highly unlikely to
activate a GIRK channel, which is classically linked to Gi/o proteins
(Dascal and Kahanovitch, 2015). Recently, 105 GPCRs were screened
for their ability to respond to 14,15 EET, but unfortunately not 11,12
EET. While several GPCRs responded to micromolecular concen-
trations of 14,15 EET (the top ﬁve all being prostaglandin receptors),
none could be identiﬁed meeting the criteria for a high-afﬁnity
receptor (Liu et al., 2016a). Similar unsatisfactory results with a
smaller number of GPCRs, none of them responsive to 14,15 EET,
were reported earlier in a study by Behm and colleagues (Behm
et al., 2009), in which 14,15 EET was ultimately identiﬁed as an
antagonist of native thromboxane receptors. Given our results, in
which 11,12 EET shows distinct actions on GIRKs, it seems desirable
to repeat these screenings with 11,12 EET.
4.3. Presynaptic effects mediated by 11,12 EET and possible
molecular targets
Both EET regioisomers and EEZE modulate the PPR of evoked
EPSCs and fEPSPS, which is consistent with a presynaptic mecha-
nism. Notably, EEZE can a) not block the 11,12 EET-mediated
reduction of EPSCs and b) changes mEPSC frequency, which 11,12
EET does not. These observations suggest distinct molecular
mechanisms and targets for EEZE and EET. Speciﬁcally, the inability
of 11,12 EET to alter mEPSC frequency strongly implies that its
potential target requires action potential-induced depolarization.
Possible candidates include therefore voltage-dependent ion
channels such as Ca2þ or Kþ channels. The BKCa channel is an
attractive candidate, given both the extensive data on its interac-
tion with EETs and the fact that it is located on presynaptic sites in
the CNS. However, at the CA3-CA1 synapse, from which we recor-
ded, BKCa channels are not recruited under basal condition, but only
under extreme conditions as in epileptic states and ischemia (Hu
et al., 2001; Runden-Pran et al., 2002). The cardiac L-type
Ca2þchannel may be another possible target. Interestingly, it is
inhibited by nanomolar concentrations of 11,12 EET (Chen et al.,
1999), but activated by higher concentrations of EETs via the
cAMP/PKA system (Xiao et al., 1998, 2004). However, data showing
CNS-residing Ca2þ channels interacting with EETs are still lacking.
Finally, members of the TRPV family might be activated by EETs in
the hippocampus. Particularly the TRPV1 channel family seems an
eligible target, as it depresses glutamatergic synaptic transmission
upon activation by another AA derivative, 12-(S)-HPETE (Gibson
et al., 2008). While this effect seems similar to the one we
observed with EETs, TRPV1 channels are exclusively located at
excitatory synapses on hippocampal interneurons, excluding them
as possible EETs targets on CA3-CA1 synapses. 11,12 EET was also
reported to activate a TRPV4-TRPC1-BKCa complex in smooth
muscle cells (Ma et al., 2015), but it remains to be proven if such
channel complexes are also existent in neurons. More work is
needed to identify the proper presynaptic targets for 11,12 and
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14,15 EETs as well as EEZE.
4.4. EEZE effects on hippocampal neurotransmission
It is difﬁcult to clearly conclude from our experiments, if the
presynaptic effect exerted by EEZE is attributable to the antago-
nization of EET- mediated action or if EEZE elicits an effect by itself.
Importantly, at least in two types of experiments EEZE was applied
alone (mEPSC recordings, Fig. 2b; fEPSP recordings, Fig. 6d) on
slices, which were not pretreated with tAUCB (tAUCB application
was limited to experiments in which EETs were washed in). Thus,
levels of ambient EETs were not elevated, making it less plausible
that EEZE action reﬂects the blockade of an augmented endogenous
EET tone.
On the postsynaptic site, EEZE unarguably failed to elicit any
antagonistic actions; in fact, it showed no postsynaptic activity at
all, since it neither modulated mEPSC kinetics and amplitudes, nor
did it affect Ihold or RMP. The inability of EEZE to antagonize EET
activity in neurons is not entirely unexpected; EEZE has shown
inconsistent effects before with the most remarkably being that it
vasodilates murine mesenteric arteries to a similar extent as a
stable EET analogue (Harrington et al., 2004).
4.5. tAUCB and its effect on fEPSPs and epileptiform activity in brain
slices
The sEHi tAUCB has been used in several recent studies to
investigate the effect of endogenous EETs (e.g. Akhnokh et al., 2016;
Imig et al., 2012). In our ﬁrst experiments focusing on EPSCs in
single cells, tAUCB alone did not show any effect; however in ﬁeld
recording, tAUCB signiﬁcantly reduced fEPSP slopes and ampli-
tudes. An explanation might be that the tAUCB effect is too small to
be successfully measured in a single neuron, but becomes apparent
when recordings from a whole population of neurons with syn-
chronized activity are carried out. In fact, in the current study a
similar phenomenon could be observed with bicuculline, as the
GABAA receptor antagonist allowed for the undisturbed isolation of
evoked EPSCs in single pyramidal cells, but led to epileptiform ac-
tivity in ﬁeld recording. Interestingly, the tAUCB effect on fEPSPs in
absence of any GABAA receptor antagonists (Fig. 6), thus with intact
inhibition, was small, since it generated on average only a 10%
reduction. Such a slight effect might be due to comparatively low
spontaneous activity and weak extracellular stimulation in the
slice, which elicits only low Ca2þ inﬂux into astrocytes and/or
neurons and results in the release of respectively low quantities of
EETs. Nevertheless, these amounts of endogenous EETs appeared to
be sufﬁcient to dampen subsequent bicuculline-induced epileptic
bursts recorded from the somata of CA1 PCs (Fig. 7). However,
tAUCB results should be interpreted with caution, as DHA or EPA-
derived epoxides may also accumulate in the presence of tAUCB
and are likely capable to interfere with neuronal transmission.
In summary, this study demonstrates for the ﬁrst time that EETs
have complex and regioisomer-speciﬁc pre- and postsynaptic ac-
tions in the hippocampus, including the 11,12 EET-mediated
opening of a GIRK channel. These ﬁndings not only reveal a so far
unknown signaling pathway of EETs, but may also help to explain
their therapeutic potential in reducing epileptiform activity.
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Abbreviations
AA: arachidonic acid
ACSF: artiﬁcial cerebrospinal ﬂuid
AUDA: 12-(3-adamantan-1-yl-ureido) dodecanoic acid
BKCa: calcium-acitivated big potassium
CA: cornu ammonis
CYP: cytochrome P450-dependent monooxygenase
DHA: docosahexaenoic acid
DHET(s): dihydroxyeicosatrienoic acid(s)
EET(s): epoxyeicosatrienoic acid(s)
EEZE: 14,15 epoxyeicosa-5(Z)-enoic acid
EPSC: excitatory postsynaptic current
EPA: eicosapentaenoic acid
fEPSP: ﬁeld excitatory postsynaptic potential
GABA: g-aminobutyric acid
GDPbS: guanosine-50-O-2-thiodiphosphate
GIRK: G protein coupled/gated inward rectifying potassium
12-HPETE: 12-hydroperoxyeicosatetraenoic acid
Ihold: holding current
mEPSC(s): miniature excitatory postsynaptic current(s)
PPR: paired pulse ratio
PC(s): pyramidal cell(s)
RMP: resting membrane potential
SC(s): Schaffer collateral(s)
sEH: soluble epoxide hydrolase
sEHi: soluble epoxide hydrolase inhibitor
tAUCB: trans-4-[4-(3-adamantan-1-y1-ureido)-cyclohexyloxy]-benzoic acid
TTQ: tertiapin Q
TTX: tetrodotoxin
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